Key Takeaways
- Loss-making quarter, timing not demand: Consolidated loss driven by a timing mismatch: new Dahej facility costs (depreciation, interest, manpower) have hit the P&L while higher-margin Krystal revenue has not yet arrived.
- Madagascar floods disrupted clove: Cyclone-driven port shutdown at Toamasina delayed raw material shipments for ~30 days, pressuring clove raw material costs, pricing, and sales in Q1.
- New product verticals are the story: Safranal, cooling agents (Gemcool 3/5/23), and phenol derivatives are all progressing through customer approvals, with meaningful revenue expected to begin Q3 FY27 and ramp through FY28.
- Management declined to guide FY27: No revenue or margin guidance for FY27; stronger guidance promised towards end of calendar year for FY28.
- What to watch next quarter: Whether Q2 export rollover materializes as shipments reach destinations, whether Safranal/Citral revenue starts meaningfully by end of Q2, and whether phenol trial production begins on schedule.
The Dahej Timing Mismatch
- Costs are live, revenue is not: The new facility's depreciation, interest, and manpower costs are already in current financials due to standby capacity, while revenue from higher-margin Krystal products has not yet entered the P&L.
- Depreciation drag: Consolidated bottom line further impacted by higher depreciation of ₹9.1 crores following capitalization of a substantial portion of the Dahej facility.
- Capex nearly complete: Of total plant capex of approximately ₹270 crores, nearly ₹265 crores already incurred and substantially capitalized.
- Margin pressure mechanics: Gross margin and EBITDA margin impacted by product mix, higher raw material cost in clove, and the operating cost base of the new facility.
- Operating leverage promise: As utilization and newer businesses gain traction, operating leverage expected to increasingly support margins and profitability over the medium term.
Aadit Shah: "Currently we're facing a timing mismatch, you know, where the cost of the new facility, the depreciation, interest, manpower cost, they are all, you know, kicked in to the current financials due to the standby capacity which has already kicked in. But however, the revenue from the higher margin product mix which is yet to come from our Krystal unit has not come in yet in our current financials."
Clove Supply Disruption
- Madagascar floods: Major cyclone in March–April caused flood-like conditions in cultivation areas; Toamasina port shut for ~30 days, causing complete slowdown of incoming raw material.
- Recovery underway: From May onwards supply has come on stream, though shipping challenges persist.
- Eugenol impact contained: Madagascar flooding and supply chain issues had some impact at the beginning of the year, but ports have opened up and material is flowing; management expects to be "fairly close" to planned numbers by year-end.
- No structural supply problem: Company is diversified in sourcing from East Africa with Madagascar and different regions producing the crop; trees are still there and producing.
- Tree regrowth timeline: Clove trees take about 2–3 years to regrow, not 10, because the company extracts from leaves.
Yash Parekh: "So, once a clove tree is out, it doesn't take up to 10 years, but may take a little bit shorter time depending on the weather conditions about 2 years to 3 years because we are effectively getting it out from the leaves, right?"
New Product Verticals
Safranal / Citral derivatives
- Commercial production commenced: Business progressing through customer approval phase and commercialization.
- Revenue timing: Contribution expected towards end of Q2 FY27 with more meaningful contribution from Q3 FY27 as commercial supplies scale up.
- Customer traction: Product successfully approved by multiple customers; strong traction hoped for in Citral vertical.
Cooling agents (Gemcool 3, 5, 23)
- Production commenced: Customer audits successfully completed; initial orders secured.
- Approved by the largest buyers: Already approved by the world's two largest companies consuming that product.
- Revenue timing: Meaningful contribution expected from Q3 FY27 as customer qualifications and recurring commercial supply scales up.
- End-use: Product largely used in oral care, confectionery, and specialty flavor segment.
- Order values not disclosed: Management explicitly declined to disclose order values or customer names.
Phenol derivatives
- Pilot batches approved: Customers want to see actual plant-level trials, which are at fairly advanced stages.
- Trial production: Expected to commence towards end of Q2 FY27 followed by product approvals and quality-related processes.
- Commercial production: Targeted during Q3 FY27 subject to completion of required approvals and quality processes; meaningful revenue contribution expected from Q4 FY27.
- Export focus: Commercial production will start generating revenues in export market by Q3 FY27 with more meaningful revenue contribution by Q4 FY27.
- Go-to-market: Targeting large MNC end customers directly, plus sizable market through traders and distributors in different geographies who will approve faster.
Multipurpose plant
- Established: Strong pipeline of specialty products focused on aroma chemicals developed; work already started on product approvals with multiple customers.
Yash Parekh: "And for cooling agents, for example, we've already been approved by the world's two largest companies who are consuming that product."
Demand Environment
- Demand is normal: Demand remains strong and back to normal levels; Q1 historically softer primarily because the larger mint vertical starts around May and June.
- Western Hemisphere ramp: Demand from Western Hemisphere (largely U.S. and Latin America) is ramping up; deal flow along with new product seasonality expected to reflect in Q2 and Q3 exports.
- Mint harvest completed: Harvest season runs May through July; harvest completed and order flow now coming in largely on the export front with shipments going through.
- Q1 export timing gap: Exports that physically occurred in May and June could not be accounted for in Q1 because shipments had not reached final destinations; rollover expected in July and August as shipments arrive.
- Q1 growth ripple: May–June is largely the mint harvest season, compounded by Madagascar clove shipment delays and shipping challenges out of India, creating a ripple effect on Q1 growth.
- Currency neutral: Currency depreciation is neither a tactical advantage nor disadvantage because the company imports, hedges foreign contracts against export realization, and subsequently exports.
Yash Parekh: "The demand remains as strong and back to normal levels."
Brazil Subsidiary & Geographic Expansion
- Brazil subsidiary approved: Represents another step toward expanding distribution reach in Latin America and creating a dedicated platform for essential oils, aromatic chemicals, and specialty chemicals.
- Western Hemisphere shipping concern: Shipping challenges to Western Hemisphere are a major concern but large part of numbers should show up by Q3 and Q4.
Working Capital & Margins
- Krystal working capital advantage: Expected to be lower than traditional Gem business because synthetic products don't require holding large inventory for many days.
- Factoring services: Company is availing factoring services to reduce debtor days.
- New product margin profile: Each new product coming in is intended to be more margin accretive than existing products.
- Margin recovery drivers: Production ramp-up is key driver; moving into value-added products across value chains; multipurpose plant and specialty aroma chemicals pipeline ready to execute.
- FY27 ramp-up year: Each vertical starting one by one; all verticals will commence this year; meaningful ramp-up and significant revenue expected through FY28, starting at the beginning of next financial year.
- Quarterly progression: Revenue from each commenced vertical will gradually increase quarter by quarter; large chunk of volumes expected through FY28.
Aadit Shah: "See, the -- we don't want to comment on that as of yet. We'll just -- you know, as the year goes by, we'll be in a better place to, you know, guide on both the revenue and the margins for FY '27."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Safranal revenue | Contribution expected towards end of Q2, more meaningful from Q3 | End of Q2 FY27 / Q3 FY27 |
| Cooling agents revenue | Meaningful contribution expected | Q3 FY27 |
| Phenol trial production | Commence towards end of Q2, followed by approvals | End of Q2 FY27 |
| Phenol commercial production | Targeted during Q3, subject to approvals and quality processes | Q3 FY27 |
| Phenol meaningful revenue | Expected in export market | Q4 FY27 |
| Eugenol ramp-up | Fairly close to planned numbers | By year-end FY27 |
| FY28 guidance | Stronger guidance to be given | Towards end of calendar year |
| FY27 guidance | Explicitly declined to guide on revenue and margins | No timeline given |
Key Metrics
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations, standalone | ₹83 cr, up from ₹76 cr in Q1 FY26 |
| Revenue from operations, consolidated | ₹99 cr, up from ₹88 cr in Q1 FY26 |
| Gross margin, standalone | 17.7%, gross profit of ₹14.7 cr |
| Gross margin, consolidated | 16.7%, gross profit of ₹16.5 cr |
| EBITDA margin, standalone | 10.3%, EBITDA of ₹8.5 cr |
| EBITDA margin, consolidated | 3.3%, EBITDA of ₹3.3 cr |
| PAT, standalone | ₹7.3 cr |
| PAT, consolidated | Loss of ₹7.9 cr |
| Cash PAT, standalone | ₹8.9 cr |
| Cash PAT, consolidated | ₹1.3 cr |
| Depreciation, consolidated | ₹9.1 cr, higher following capitalization of substantial portion of Dahej facility |
| Total plant capex, Dahej | ~₹270 cr, of which nearly ₹265 cr incurred and substantially capitalized |
| Krystal revenue share outlook | More than 50% of overall revenue through FY28 |
| Cooling agents capacity utilization | ~25% on 500-ton capacity expected this year, per analyst suggestion with management indicating "fairly close to those numbers" |
| Madagascar port shutdown | ~30 days due to cyclone and flooding, impacting clove raw material availability |